Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy

BJU International

Volumn 102, Issue 9, 2008, Pages 1086-1091

  Tagawa, Scott T ^a,c   Dorff, Tanya B ^a   Rochanda, Leanne ^a   Ye, Wei ^a   Boyle, Soames ^a   Raghavan, Derek ^b   Lieskovsky, Gary ^c   Skinner, Donald G ^c   Quinn, David I ^c   Liebman, Howard A ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Haemorrhage; Haemostasis; Prostatectomy; Prostatic neoplasm

Indexed keywords

D DIMER; PROSTATE SPECIFIC ANTIGEN; THROMBIN ANTITHROMBIN COMPLEX;

AGED; ARTICLE; BLEEDING; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTITHROMBIN III; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE HYDROLASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 53849100682     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07780.x     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004 172 : 910 4
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003 169 : 517 23
4. Gerber GS, Thisted RA, Scardino PT et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996 276 : 615 9
5. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 84
6. Trousseau A. Phlegmasia alba dolens. In : Trousseau A, ed. Clinique medicinale de l'Hotel-Dieu de Paris. Paris : Bailliere JB et fils, 1865 : 645 712
7. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992 11 : 237 48
8. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979 71 : 10 6
9. Falanga A, Ofosu FA, Cortelazzo S et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993 85 : 745 50
10. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost 2003 29 : 301 8
11. Tagnon HJ, Whitmore WF Jr, Schulman P, Kravitz SC. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 1953 6 : 63 7
12. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002 13 : 1 5
13. Rapaport SI. Preoperative hemostatic evaluation: which tests, if any? Blood 1983 61 : 229 31
14. de Moerloose P. Laboratory evaluation of hemostasis before cardiac operations. Ann Thorac Surg 1996 62 : 1921 5
15. Kozak EA, Brath LK. Do 'screening' coagulation tests predict bleeding in patients undergoing fiberoptic bronchoscopy with biopsy? Chest 1994 106 : 703 5
16. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 23 : 7005 12
17. Blackwell K, Haroon Z, Broadwater G et al. Plasma d-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000 18 : 600 8
18. Buccheri G, Torchio P, Ferrigno D. Plasma levels of d-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003 97 : 3044 52
19. Dirix LY, Salgado R, Weytjens R et al. Plasma fibrin d-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002 86 : 389 95
20. Seitz R, Heidtmann HH, Wolf M, Immel A, Egbring R. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol 1997 8 : 781 4
21. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma d-dimer levels in patients with lung cancer. Thorax 1997 52 : 563 5
22. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997 77 : 456 61
23. Korte W, Truttmann B, Heim C, Stangl U, Schmid L, Kreienbuhl G. Preoperative values of molecular coagulation markers identify patients at low risk for intraoperative haemostatic disorders and excessive blood loss. Clin Chem Lab Med 1998 36 : 235 40
24. Korte W, Gabi K, Rohner M et al. Preoperative fibrin monomer measurement allows risk stratification for high intraoperative blood loss in elective surgery. Thromb Haemost 2005 94 : 211 5
25. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 2002 88 : 213 20
26. Farnham SB, Webster TM, Herrell SD, Smith JA Jr. Intraoperative blood loss and transfusion requirements for robotic-assisted radical prostatectomy versus radical retropubic prostatectomy. Urology 2006 67 : 360 3
27. Tewari A, Srivasatava A, Menon M, Members of the VIP Team. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int 2003 92 : 205 10
28. Brown JA, Garlitz C, Gomella LG, McGinnis DE, Diamond SM, Strup SE. Perioperative morbidity of laparoscopic radical prostatectomy compared with open radical retropubic prostatectomy. Urol Oncol 2004 22 : 102 6
29. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002 346 : 1138 44
30. Nuttall M, van der Meulen J, Phillips N et al. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol 2004 172 : 2145 52
31. Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. J Urol 2005 174 : 432 8
32. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999 91 : 1950 6
33. Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. Urology 2004 64 : 117 22
34. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003 21 : 401 5